Debu Tripathy (University of Texas MD Anderson Cancer Center, Houston, TX, USA) and colleagues presented an interim analysis of the randomised, phase 3, MONALEESA-2 trial, the first trial investigating the addition of cyclin D1/CDK4/6 inhibitor ribociclib to standard hormone therapy in women with premenopausal or perimenopausal, hormone receptor–positive (HR-positive), HER2-negative advanced breast cancer. 672 patients were randomly assigned (1:1) to ribociclib (600 mg per day, 3-weeks on, 1-week off; n=335) or placebo (n=337) in combination with tamoxifen (20 mg per day) or a nonsteroidal aromatase inhibitors (letrozole [2·5 mg per day] or anastrozole [1 mg per day]) plus goserelin (3·6 mg every 28 days).

中文翻译：

---

2017年圣安东尼奥乳腺癌研讨会

Debu Tripathy（美国德克萨斯州休斯敦的德克萨斯大学安德森分校癌症中心）及其同事对MONALEESA-2随机第3期临床试验进行了中期分析，这是第一个研究细胞周期蛋白D1 / CDK4 / 6抑制剂ribociclib的试验。对绝经前或绝经前，激素受体阳性（HR阳性），HER2阴性的晚期乳腺癌女性进行标准激素治疗。672例患者被随机分配（1：1）接受ribociclib（每天600 mg，3周开，1周以下; n = 335）或安慰剂（n = 337）联合他莫昔芬（每天20 mg）或非甾体芳香酶抑制剂（来曲唑[每天2·5毫克]或阿那曲唑[每天1毫克]）加戈舍瑞林（每28天3·6毫克）。